In lung cancer [43] and ovarian cancer [39], overexpressing MACC1 has been demonstrated to overcome chemotherapeutic resistance, and down-regulating MACC1 expression has been found to increase the sensitivity of cisplatin-resistant cancer cells to the drug [44]. Here, MACC1 is linked to ovarian cancer.